Impact of Neoadjuvant Hormonal Therapy on the Surgical Management of Extensive Ductal Carcinomas in Situ
Status:
Not yet recruiting
Trial end date:
2033-08-01
Target enrollment:
Participant gender:
Summary
Ductal carcinoma in situ (DCIS) accounts for approximately 20% of newly diagnosed breast
cancer cases. Of these women, 20% require radical management in the form of mastectomy
because of the extent of the lesions, which most often manifest as diffuse
microcalcifications.
This mutilating surgical management contrasts with the excellent prognosis of this pathology
and considerably alters the quality of life of patients.
Neoadjuvant hormone therapy has shown its efficacy in hormone-dependent infiltrating ductal
carcinomas and offers the possibility of conservative surgery after hormone therapy.
Adjuvant hormone therapy with Tamoxifen or anti-aromatase drugs has shown its efficacy in the
prevention of homo or contralateral recurrence.
The HORNEO 01 trial fits perfectly in the current context of surgical de-escalation of ductal
carcinomas in situ. The objective of the study is to evaluate the impact of neoadjuvant
hormone therapy on the surgical management of extensive DCIS.